Detalhe da pesquisa
1.
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
Clin Gastroenterol Hepatol
; 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993033
2.
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
Lancet
; 395(10217): 53-64, 2020 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31813637
3.
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).
Ann Rheum Dis
; 80(8): 1022-1030, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958326
4.
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).
Ann Rheum Dis
; 79(2): 176-185, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685553
5.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Qual Life Res
; 29(2): 369-380, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655974
6.
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
Lancet
; 392(10163): 2441-2451, 2018 12 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30360964
7.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
J Am Acad Dermatol
; 75(6): 1156-1161, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27692498
8.
Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.
J Rheumatol
; 50(6): 754-762, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725056
9.
Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
J Crohns Colitis
; 17(7): 1066-1078, 2023 Jul 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738443
10.
Effects of ixekizumab treatment on structural changes in the sacroiliac joint: MRI assessments at 16 weeks in patients with non-radiographic axial spondyloarthritis.
Lancet Rheumatol
; 4(9): e626-e634, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288892
11.
Spinal Radiographic Progression and Predictors of Progression in Patients With Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years.
J Rheumatol
; 49(3): 265-273, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34853086
12.
Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies.
J Rheumatol
; 48(2): 188-197, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32669450
13.
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Arthritis Rheumatol
; 71(4): 599-611, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30343531
14.
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1).
J Rheumatol
; 45(3): 367-377, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29247148
15.
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis.
J Rheumatol
; 43(2): 289-97, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26669919
16.
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
Pharmacol Res
; 46(3): 295-300, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12220974